Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hjernestimulation for fodsålsfornemmelse hos ældre voksne med somatosensoriske underskud af fodsål (BSFS)

18. september 2026 opdateret af: Hebrew SeniorLife

Kortikale mekanismer og modulering af somatosensation hos ældre voksne med fodsål somatosensoriske svækkelser

In older adults, diminished sensation of the legs and feet is highly prevalent and causes poor balance and reduced mobility. This type of sensation is not only dependent upon the receptors and nerves in the legs and feet, but also upon a complex central nervous system pathway that includes the cerebral cortex of the brain. This project will use a form of noninvasive brain stimulation called transcranial direct current stimulation (tDCS) to test whether increasing the excitability of the brain networks that process sensory feedback can augment foot sole sensation, balance, and mobility in older adults suffering from mild-to-moderate foot sole sensory impairments.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

20

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Aged ≥65 years.
  2. Self-reported feeling of unsteadiness or difficulty when standing and walking.
  3. Mild-to-moderate foot-sole somatosensory impairment: the ability to perceive 75g monofilament but inability to perceive 10g monofilament.

Exclusion Criteria:

  1. self-reported inability to stand or walk continuously for one minute without personal assistance (canes or walkers allowed);
  2. history or presence of foot ulceration, amputation, or deformities;
  3. self-reported uncontrolled pain or pain that is associated with mobility disability;
  4. uncontrolled diabetes mellitus;
  5. hospitalization within the past three months due to acute illness, or as the result of a musculoskeletal injury significantly affecting balance;
  6. persistent severe pain of lower extremity when standing or walking;
  7. diagnosis of dementia, Parkinson's disease, or stroke that affects balance;
  8. unstable medical condition;
  9. legal blindness or deafness;
  10. uncontrolled hypertension (i.e., systolic BP >180, diastolic BP >100 mm Hg, or prescription of ≥3 anti-hypertensive medications);
  11. functionally limiting nephropathy, severe diseases or transplant of the kidney or liver, renal or congestive heart failure;
  12. active cancer treatment;
  13. balance disorders due to past use of chemotherapy or history of Guillain-Barré syndrome;
  14. use of neuro-active or recreational drugs (e.g., sedatives, anti-psychotics), or alcohol abuse, which may affect the brain excitability;
  15. contraindications to MRI or tDCS (e.g., personal or family history of seizures or epilepsy, metallic or electric bio-implants, claustrophobia, brain surgery);
  16. persistent vertigo;
  17. history of Charcot-Marie-Tooth nerve disease.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: tDCS group

Participants in this arm will receive the real tDCS intervention.

tDCS can safely and selectively modulate cortical excitability (specifically neuronal firing likelihood) by transferring weak electrical currents between scalp electrodes. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA in this study.

Sham-komparator: sham group

Participants in this arm will receive the sham stimulation as control.

sham stimulation will implement the same protocol of the tDCS intervention; however, only very low-level currents (no more than 0.5 mA) are transferred between the same electrodes used for the tDCS throughout the 20-minute session. This strategy effectively mimics the cutaneous sensations and skin redness induced by creating only micro cortical electric fields.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
postural sway area when standing with eyes closed on the foam
Tidsramme: Before and immediately after intervention

This metric assesses the degree to which the soft support and cut-off of the vision diminishes the control of standing posture.

Before and immediately after intervention
Timed Up-and-Go (TUG) time
Tidsramme: Before and immediately after intervention

This metric assesses mobility.

Before and immediately after intervention
On-target Blood oxygen level dependent (BOLD) signal intensity in response to foot sole stimulation
Tidsramme: Before and immediately after intervention

This metric assesses the degree to which brain cortical regions activated by the walking-related foot-sole stimulation.

Before and immediately after intervention
Standing vibratory thresholds of each foot sole
Tidsramme: Before and immediately after intervention

This metric assesses the degree to which the foot soles can sense the vibro-tactile stimuli when standing.

Before and immediately after intervention

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postural sway speed when standing with eyes closed on the foam
Tidsramme: Before and immediately after intervention

This metric assesses the degree to which the soft support and cut-off of the vision diminishes the control of standing posture.

Before and immediately after intervention
Gait speed of 10m walking test
Tidsramme: Before and immediately after intervention

This metric assesses mobility.

Before and immediately after intervention

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
BOLD signal intensity within other relevant cortical regions in response to foot sole stimulation
Tidsramme: Before and immediately after intervention

This metric assesses the degree to which brain cortical regions activated by the walking-related foot-sole stimulation.

Before and immediately after intervention

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. februar 2026

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

8. januar 2025

Først indsendt, der opfyldte QC-kriterier

8. januar 2025

Først opslået (Faktiske)

13. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner